Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study

Pierfrancesco Bassi; Andrea Volpe; Daniele D'Agostino; Giuseppe Palermo; D Renier; S Franchini; A Rosato; Marco Racioppi

doi:10.1016/j.juro.2010.09.073

Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study

Pierfrancesco Bassi, Andrea Volpe, Daniele D'Agostino, Giuseppe Palermo, D Renier, S Franchini, A Rosato, Marco Racioppi

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Carcinoma in situ represents high grade anaplasia of the bladder mucosa. Intravesical immunotherapy with bacillus Calmette-Guérin is the gold standard treatment for patients with carcinoma in situ. Patients with carcinoma in situ refractory to bacillus Calmette-Guérin are candidates for major surgery such as radical cystectomy. We identified the maximum tolerated dose and the recommended dose, and evaluated the safety profile of paclitaxel-hyaluronic acid bioconjugate given by intravesical instillation to patients with carcinoma in situ refractory to bacillus Calmette-Guérin.

Lingua originale	English
pagine (da-a)	445-449
Numero di pagine	5
Rivista	THE JOURNAL OF UROLOGY
Volume	185
DOI	https://doi.org/10.1016/j.juro.2010.09.073
Stato di pubblicazione	Pubblicato - 2011

Keywords

Adjuvants, Immunologic
Administration, Intravesical
Adolescent
Adult
Aged
Aged, 80 and over
BCG Vaccine
Biopsy, Needle
Carcinoma in Situ
Cystoscopy
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Neoplasm
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Hyaluronic Acid
Italy
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Staging
Paclitaxel
Patient Selection
Survival Analysis
Treatment Outcome
Urinary Bladder Neoplasms
Young Adult

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.juro.2010.09.073

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{a8d422eecaf949b5be6024cefbe2acba,

title = "Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Gu{\'e}rin refractory carcinoma in situ of the bladder: results of a phase I study",

abstract = "Carcinoma in situ represents high grade anaplasia of the bladder mucosa. Intravesical immunotherapy with bacillus Calmette-Gu{\'e}rin is the gold standard treatment for patients with carcinoma in situ. Patients with carcinoma in situ refractory to bacillus Calmette-Gu{\'e}rin are candidates for major surgery such as radical cystectomy. We identified the maximum tolerated dose and the recommended dose, and evaluated the safety profile of paclitaxel-hyaluronic acid bioconjugate given by intravesical instillation to patients with carcinoma in situ refractory to bacillus Calmette-Gu{\'e}rin.",

keywords = "Adjuvants, Immunologic, Administration, Intravesical, Adolescent, Adult, Aged, Aged, 80 and over, BCG Vaccine, Biopsy, Needle, Carcinoma in Situ, Cystoscopy, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hyaluronic Acid, Italy, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Paclitaxel, Patient Selection, Survival Analysis, Treatment Outcome, Urinary Bladder Neoplasms, Young Adult, Adjuvants, Immunologic, Administration, Intravesical, Adolescent, Adult, Aged, Aged, 80 and over, BCG Vaccine, Biopsy, Needle, Carcinoma in Situ, Cystoscopy, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hyaluronic Acid, Italy, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Paclitaxel, Patient Selection, Survival Analysis, Treatment Outcome, Urinary Bladder Neoplasms, Young Adult",

author = "Pierfrancesco Bassi and Andrea Volpe and Daniele D'Agostino and Giuseppe Palermo and D Renier and S Franchini and A Rosato and Marco Racioppi",

year = "2011",

doi = "10.1016/j.juro.2010.09.073",

language = "English",

volume = "185",

pages = "445--449",

journal = "THE JOURNAL OF UROLOGY",

issn = "0022-5347",

publisher = "Lippincott, Williams & Wilkins:530 Walnut Street:Philadelphia, PA 19106:(800)638-3030, (301)223-2300, EMAIL: orders@lww.com, INTERNET: http://www.lww.com, Fax: (301)223-2320, (301)223-2320",

}

TY - JOUR

T1 - Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study

AU - Bassi, Pierfrancesco

AU - Volpe, Andrea

AU - D'Agostino, Daniele

AU - Palermo, Giuseppe

AU - Renier, D

AU - Franchini, S

AU - Rosato, A

AU - Racioppi, Marco

PY - 2011

Y1 - 2011

N2 - Carcinoma in situ represents high grade anaplasia of the bladder mucosa. Intravesical immunotherapy with bacillus Calmette-Guérin is the gold standard treatment for patients with carcinoma in situ. Patients with carcinoma in situ refractory to bacillus Calmette-Guérin are candidates for major surgery such as radical cystectomy. We identified the maximum tolerated dose and the recommended dose, and evaluated the safety profile of paclitaxel-hyaluronic acid bioconjugate given by intravesical instillation to patients with carcinoma in situ refractory to bacillus Calmette-Guérin.

AB - Carcinoma in situ represents high grade anaplasia of the bladder mucosa. Intravesical immunotherapy with bacillus Calmette-Guérin is the gold standard treatment for patients with carcinoma in situ. Patients with carcinoma in situ refractory to bacillus Calmette-Guérin are candidates for major surgery such as radical cystectomy. We identified the maximum tolerated dose and the recommended dose, and evaluated the safety profile of paclitaxel-hyaluronic acid bioconjugate given by intravesical instillation to patients with carcinoma in situ refractory to bacillus Calmette-Guérin.

KW - Adjuvants, Immunologic

KW - Administration, Intravesical

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - BCG Vaccine

KW - Biopsy, Needle

KW - Carcinoma in Situ

KW - Cystoscopy

KW - Disease-Free Survival

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Drug Resistance, Neoplasm

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hyaluronic Acid

KW - Italy

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Neoplasm Staging

KW - Paclitaxel

KW - Patient Selection

KW - Survival Analysis

KW - Treatment Outcome

KW - Urinary Bladder Neoplasms

KW - Young Adult

KW - Adjuvants, Immunologic

KW - Administration, Intravesical

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - BCG Vaccine

KW - Biopsy, Needle

KW - Carcinoma in Situ

KW - Cystoscopy

KW - Disease-Free Survival

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Drug Resistance, Neoplasm

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hyaluronic Acid

KW - Italy

KW - Male

KW - Maximum Tolerated Dose

KW - Middle Aged

KW - Neoplasm Staging

KW - Paclitaxel

KW - Patient Selection

KW - Survival Analysis

KW - Treatment Outcome

KW - Urinary Bladder Neoplasms

KW - Young Adult

UR - http://hdl.handle.net/10807/2113

U2 - 10.1016/j.juro.2010.09.073

DO - 10.1016/j.juro.2010.09.073

M3 - Article

SN - 0022-5347

VL - 185

SP - 445

EP - 449

JO - THE JOURNAL OF UROLOGY

JF - THE JOURNAL OF UROLOGY

ER -

Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo